Clinical Trials Sponsored by GlaxoSmithKline

Total 4767 results

GlaxoSmithKline

Completed

Anti-MAG First Administration to Human

Cerebrovascular Accident

United States, Australia
GlaxoSmithKline

Completed

SAP Depleter Dose Escalation Study in Healthy Volunteers

Amyloidosis

United Kingdom
GlaxoSmithKline

Completed

A Study Assessing GW870086's Potential to Cause Skin Thinning

Dermatitis, Atopic

Germany
GlaxoSmithKline

Completed

A Healthy Volunteer Study With Inhaled GSK573719 and Placebo

Pulmonary Disease, Chronic Obstructive

Belgium
GlaxoSmithKline

Completed

A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.

Asthma

Czechia, Slovakia
GlaxoSmithKline

Completed

GSK706769/KALETRA Drug-drug Interaction Study

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

Drug Interaction Study to Investigate Co-administration of GW642444M With Ketoconazole

Pulmonary Disease, Chronic Obstructive

Australia
GlaxoSmithKline

Completed

A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder

Social Phobia

Spain
GlaxoSmithKline

Completed

Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer

Carcinoma, Hepatocellular

Taiwan, Thailand, Hong Kong
GlaxoSmithKline

Completed

Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.

Schizophrenia

Spain
GlaxoSmithKline

Completed

This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets. (BA/BE: 250/12)

Arthritis, Rheumatoid
GlaxoSmithKline

Completed

A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects

Infections, Respiratory Tract

United Kingdom
GlaxoSmithKline

Completed

Intranasal SB-705498 in Healthy Volunteers

Rhinitis

United Kingdom
GlaxoSmithKline

Completed

A Study To Assess The Effect Of SB-705498 In A Capsaicin Challenge Model

Rhinitis

Netherlands
GlaxoSmithKline

Completed

A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Primary Insomnia

Sleep Initiation and Maintenance Disorders

Germany
GlaxoSmithKline

Completed

ARI103094-Follow-Up Study for REDUCE Study Subjects

Neoplasms, Prostate

France, Germany, Spain, United States, Netherlands, Canada, United Kingdom, Finland, Chile, Sweden, Argentina, Greece
GlaxoSmithKline

Completed

A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma

Lymphoma, Follicular
GlaxoSmithKline

Completed

Treatment Of Patients With Social Anxiety Disorder

Social Phobia

United States, Canada, Germany, Sweden, Finland, Norway, South Africa
GlaxoSmithKline

Completed

Investigation of Iron Uptake From Micronutrient Fortified Powder Versus From Tailored Control in Milk

Growth and Development

India
GlaxoSmithKline

Completed

A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.

Dyslipidaemias

United States
GlaxoSmithKline

Completed

Blood Levels and Effects of GSK1325756 in Healthy Adult Volunteers Aged 40 to 80 Years Old

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers

Diabetes Mellitus, Type 2

United Kingdom
GlaxoSmithKline

Terminated

Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome

Hypereosinophilic Syndrome

United States, Belgium, Canada, Germany, Italy, France, Australia
GlaxoSmithKline

Completed

Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

Asthma
GlaxoSmithKline

Completed

Cancer in Patients With Gabapentin (GPRD)

Epilepsy | Renal Cell Carcinoma | Diabetes | Stomach Cancer | Cancer | Breast Cancer | Pancreatic Cancer | Bladder Cancer | Chronic Pancreatitis | Renal Cancer | Anal Cancer | Renal Pelvis Cancer | Pain, Neuropathic | Nervous System Cancer | Penis Cancer | Bone and Joint Cancer
GlaxoSmithKline

Completed

ULTIVA Post Marketing Surveillance

Analgesia
GlaxoSmithKline

Terminated

Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia

Telangiectasia, Hereditary Hemorrhagic

United States, Canada
GlaxoSmithKline

Completed

AVODART(Dutasteride) Post-marketing Surveillance(PMS) (AVO PMS)

Prostatic Hyperplasia | Benign Prostatic Hyperplasia

Korea, Republic of
GlaxoSmithKline

Completed

Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

Pulmonary Disease, Chronic Obstructive

United States, Germany
GlaxoSmithKline

Completed

A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel

Pain

United States
GlaxoSmithKline

Completed

An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.

Rhinitis, Allergic, Seasonal

Netherlands
GlaxoSmithKline

Completed

A Safety Study to Investigate the Skin Sensitization Potential of MFC51123

Pain

United States
GlaxoSmithKline

Completed

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity

Cerebrovascular Accident

China
GlaxoSmithKline

Terminated

A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study (Relative Bio)

Community-acquired Infection

Australia
GlaxoSmithKline

Completed

GSK2251052 Mass Balance in Healthy Adult Subjects

Community-acquired Infection

Netherlands
GlaxoSmithKline

Completed

A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719

Pulmonary Disease, Chronic Obstructive

Netherlands
GlaxoSmithKline

Completed

Helium-3 MRI Imaging Study in COPD

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Alcohol Interaction Study

Alcoholism

Netherlands
GlaxoSmithKline

Completed

Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing

Asthma

New Zealand, South Africa
GlaxoSmithKline

Completed

GSK618334 Repeat Dose Study

Substance Dependence

United Kingdom
GlaxoSmithKline

Completed

Repeat Dose Safety Study for Compound to Treat Anemia

Kidney Disease

Australia
GlaxoSmithKline

Completed

Characterisation of Healthy Volunteers, Asthma and Chronic Obstructive Pulmonary Disease Patients for Inhalation Profile, Pharyngometry, Spirometric Indices and Lung Morphometry

Pulmonary Disease, Chronic Obstructive

Belgium
GlaxoSmithKline

Completed

Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate is Processed by the Body in Healthy Caucasian, Japanese, Korean and Chinese Subjects

Asthma

Australia
GlaxoSmithKline

Completed

Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

Rosuvastatin Calcium Bioequivalence Study - Fast

Hypercholesterolaemia

Brazil
GlaxoSmithKline

Completed

Bioequivalence Study of 300 mg Gabapentin

Epilepsy
GlaxoSmithKline

Completed

Bioequivalence Trial of Alprazolam 2 mg Tablets

Anxiety Disorders
GlaxoSmithKline

Completed

Bioequivalence - Duodart Against Avodart & Omnic

Prostatic Hyperplasia

Russian Federation
GlaxoSmithKline

Completed

A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.

Migraine Disorders

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b (Hib)

3

Subscribe